Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Iroko
>
Our "wonderful" OA Study
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="Anonymous, post: 5196064"]You really don't know what you are talking about! This was a placebo controlled trial. This a was a summary of the study "The authors reported that treatment with Zorvolex 35 mg tid “significantly improved WOMAC pain subscale scores from baseline at 12 weeks (−44.1; p = 0.0024) compared with placebo (−32.5).” Although treatment with Zorvolex 35 mg bid “provided numerical improvement in pain at week 12” compared with placebo, the results did not reach statistical significance."</p><p><br /></p><p>After 12 weeks this drug for which wis meant for chronic use is no better than placebo. I don't know where you get from this study that it is meant to show similar efficacy with a reduced dose. If that's what they were looking for than they should have study Zorvolex versus higher strength diclofenac.</p><p><br /></p><p>The data shows that for 12 weeks that the drug is more effective than placebo, as all other studies it says nothing about how it compares to other diclofenacs which is the major hurdle.[/QUOTE]</p><p><br /></p>
[QUOTE="Anonymous, post: 5196064"]You really don't know what you are talking about! This was a placebo controlled trial. This a was a summary of the study "The authors reported that treatment with Zorvolex 35 mg tid “significantly improved WOMAC pain subscale scores from baseline at 12 weeks (−44.1; p = 0.0024) compared with placebo (−32.5).” Although treatment with Zorvolex 35 mg bid “provided numerical improvement in pain at week 12” compared with placebo, the results did not reach statistical significance." After 12 weeks this drug for which wis meant for chronic use is no better than placebo. I don't know where you get from this study that it is meant to show similar efficacy with a reduced dose. If that's what they were looking for than they should have study Zorvolex versus higher strength diclofenac. The data shows that for 12 weeks that the drug is more effective than placebo, as all other studies it says nothing about how it compares to other diclofenacs which is the major hurdle.[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Iroko
>
Our "wonderful" OA Study
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Iroko
>
Our "wonderful" OA Study
>